Commonwealth Equity Services’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Commonwealth Equity Services’s Portfolio IMUC Stock Details IMUC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-650	Closed	-$3K	–	2422
2016 Q3	$3K	Sell	650 -25	-4%	-$161	﹤0.01%	2252
2016 Q2	$6K	Hold	675	–	–	﹤0.01%	2229
2016 Q1	$8K	Hold	675	–	–	﹤0.01%	2197
2015 Q4	$10K	Hold	675	–	–	﹤0.01%	2172
2015 Q3	$11K	Buy	+675	New	+$12.3K	﹤0.01%	2121

Other funds holding IMUC

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Intellectus Partners San Francisco, California $578M AUM 49.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Commonwealth Equity Services's IMUC Position: Q4 2016 in Review

Commonwealth Equity Services sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q4 2016, closing a stake of 650 shares — an estimated $3K sold.

Commonwealth Equity Services first reported a position in IMUC in Q3 2015 and held it in 5 quarters. The position peaked at $11K in Q3 2015. 16 funds tracked by Wall St. Rank hold IMUC as of Q4 2016.

Commonwealth Equity Services reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q4 2016 after selling out during the quarter.
Commonwealth Equity Services sold 650 ImmunoCellular Therapeutics, Ltd. shares in Q4 2016, an estimated $3K.
Commonwealth Equity Services first reported a position in ImmunoCellular Therapeutics, Ltd. in Q3 2015 and held it in 5 quarters.
Commonwealth Equity Services's ImmunoCellular Therapeutics, Ltd. position peaked at $11K in Q3 2015.
16 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q4 2016.

Based on Commonwealth Equity Services's 13F filing for Q4 2016, filed 1 Feb 2017.